PREMPRO (conjugated estrogens and medroxyprogesterone acetate) by Pfizer is estrogen receptor agonists [moa]. First approved in 1995.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
PREMPRO is an oral combination hormone replacement therapy (HRT) containing conjugated estrogens and medroxyprogesterone acetate. It works by binding to estrogen receptors to relieve vasomotor symptoms (hot flashes, night sweats) and other menopausal symptoms in postmenopausal women. The fixed-dose combination balances estrogen with progestin to reduce endometrial hyperplasia risk associated with estrogen monotherapy.
Product approaching loss of exclusivity with modest current market presence; commercial teams face declining revenue and shrinking headcount.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women
Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation
Worked on PREMPRO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on PREMPRO offers minimal career growth opportunities given its LOE-approaching status and zero linked job openings. Roles on this product are typically maintenance-focused rather than development-oriented, making it less attractive for ambitious professionals seeking launch experience or portfolio expansion.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo